Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK.
Vertex Pharmaceuticals Europe Ltd, Milton Park, Abingdon, UK.
Nat Genet. 2018 Aug;50(8):1122-1131. doi: 10.1038/s41588-018-0173-1. Epub 2018 Jul 27.
The molecular mechanisms underpinning susceptibility loci for type 2 diabetes (T2D) remain poorly understood. Coding variants in peptidylglycine α-amidating monooxygenase (PAM) are associated with both T2D risk and insulinogenic index. Here, we demonstrate that the T2D risk alleles impact negatively on overall PAM activity via defects in expression and catalytic function. PAM deficiency results in reduced insulin content and altered dynamics of insulin secretion in a human β-cell model and primary islets from cadaveric donors. Thus, our results demonstrate a role for PAM in β-cell function, and establish molecular mechanisms for T2D risk alleles at this locus.
2 型糖尿病(T2D)易感基因座的分子机制仍知之甚少。肽基甘氨酸 α-酰胺化单加氧酶(PAM)中的编码变异与 T2D 风险和胰岛素生成指数都有关联。在此,我们证明 T2D 风险等位基因通过表达和催化功能缺陷对整体 PAM 活性产生负面影响。PAM 缺乏导致人类β细胞模型和尸体供者原代胰岛中胰岛素含量减少和胰岛素分泌动力学改变。因此,我们的结果表明 PAM 在β细胞功能中的作用,并确定了该基因座 T2D 风险等位基因的分子机制。